Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Patient Profile Presentation: A 70-Year-Old Man with Stage 4 Clear Cell RCC

June 8th 2022

Dr Elan Diamond presents the patient profile of a 70-year-old man with stage IV clear cell renal cell carcinoma.

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Lenvatinib Plus Pembrolizumab Improves PFS2 Outcomes in Advanced RCC

June 5th 2022

Patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab experienced a longer time to progression on next line of therapy compared with those who received sunitinib.

Adjuvant Everolimus Displays RFS Benefit in Very High-Risk RCC

June 4th 2022

Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma.

Sequencing Therapies for Advanced RCC

June 2nd 2022

Experts discuss how they sequence I/O–TKI treatments for advanced renal cell carcinoma.

Toxicities with IO-TKI Combination Regimens for Advanced RCC and Their Management

June 2nd 2022

Elan Diamond, MD, explains toxicities commonly seen with I/O–TKI combination regimens, how to manage them, and how to discuss toxicities with patients with advanced renal cell carcinoma.

OncLive Honors 13 Cancer Care Pioneers

June 2nd 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Heightened Histological Focus Fosters Treatment Advances in Non-clear Cell RCC

June 1st 2022

Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.

Dr. Vaishampayan on the Rationale of the PROBE Trial in RCC

June 1st 2022

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.

Dr. Daneshmand on Emerging Treatments in Bladder Cancer

May 26th 2022

Sia Daneshmand MD, discusses emerging treatments in bladder cancer.

Front-Line Lenvatinib + Pembrolizumab Combination Regimens for Advanced RCC: Selecting Patients and Dose

May 25th 2022

A review of the first-line I/O-TKI combination regimens available for advanced RCC and selecting the right patients and dose for treatment with lenvatinib and pembrolizumab.

Patient Profile Presentation: A 56-Year-Old Man with Metastatic Clear Cell RCC

May 25th 2022

Robert Alter, MD, presents the patient profile of a 56-year-old man with metastatic clear cell renal cell carcinoma presenting with chromaturia.

Nivolumab Plus Axitinib Generates Promising Responses in Untreated Advanced RCC

May 24th 2022

The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.

Kevin Hakimi on the Rationale of the PADRES Trial in RCC

May 24th 2022

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.

Unmet Needs and Future Perspectives in Advanced RCC

May 18th 2022

The panel concludes with final thoughts on unmet needs and future perspectives for the treatment of advanced clear-cell RCC.

Is There a Role for Cabozantinib in the First-Line Setting in Advanced RCC in Certain Populations?

May 18th 2022

Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.

Sequencing Therapies in the Second Line and Beyond in Advanced RCC

May 18th 2022

Dr Barata comments on sequencing therapies in the second line and beyond in patients with advanced RCC.

Dr. Ornstein on Unmet Needs in Refractory RCC

May 17th 2022

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Fleming on the KEYNOTE-426 Trial in Metastatic RCC

May 17th 2022

Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.

Pal Discusses Eye-Catching ASCO GU Data in RCC

May 16th 2022

Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.